Lee's Pharmaceutical Holdings (0950) is a HK-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of HK$689M, trading at HK
.17 on the HKSE. This SniperIQ fundamentals page covers Lee's Pharmaceutical Holdings's valuation (P/E 7.5x, P/B 0.3x), profitability (net margin 6.4%), revenue (HK
.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapHK$689M
P/E (TTM)7.5x
Net Margin6.4%
Revenue (FY25)HK
.4B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Lee's Pharmaceutical Holdings's market cap?
Lee's Pharmaceutical Holdings (0950) has a market capitalization of approximately HK$689M, trading at HK
.17 on the HKSE. Market cap moves with the live share price.
What is Lee's Pharmaceutical Holdings's P/E ratio?
Lee's Pharmaceutical Holdings's trailing twelve-month P/E ratio is 7.5x, with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lee's Pharmaceutical Holdings?
Lee's Pharmaceutical Holdings runs a net profit margin of 6.4%, a gross margin of 50.8%, and an operating margin of 6.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lee's Pharmaceutical Holdings generate?
Lee's Pharmaceutical Holdings reported revenue of HK
.4B for fiscal year 2025, with net income of HK$92M and earnings per share (EPS) of 0.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lee's Pharmaceutical Holdings pay a dividend?
Lee's Pharmaceutical Holdings offers a trailing dividend yield of about 3.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Lee's Pharmaceutical Holdings financially healthy?
Lee's Pharmaceutical Holdings carries a debt-to-equity ratio of 0.15x and a current ratio of 1.03x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lee's Pharmaceutical Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lee's Pharmaceutical Holdings (0950) the key facts are: market cap HK$689M, P/E 7.5x, revenue HK
.4B, 52-week range 0.99-2.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Lee's Pharmaceutical Holdings's full fundamentals live
Get Lee's Pharmaceutical Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.